Dexmedetomidine injection is indicated for sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. Dexmedetomidine injection should be administered by continuous infusion not to exceed 24 hours. Dexmedetomidine injection has been continuously infused in mechanically ventilated adult patients prior to extubation, during extubation, and post-extubatio...
• Dexmedetomidine injection dosing should be individualized and titrated to desired clinical response. • Dexmedetomidine injection is not indicated for infusions lasting longer than 24 hours. • Dexmedetomidine injection should be administered using a controlled infusion device. Table 1: Recommended Dosage in Adult Patients INDICATION DOSAGE AND ADMINISTRATION Initiation of Intensive Care Unit Sedation For adult p...
Dexmedetomidine Injection USP, 200 mcg/2 mL (100 mcg/mL) is clear and colorless and is available in: NDC 67457-251-02 2 mL in a 3 mL single-dose vial, cartons of 25 Do not use if product is discolored or if precipitate matter is present. The strength is based on the dexmedetomidine base. Discard unused portion. Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]
www.fda.gov/medwatchDexmedetomidine injection is indicated for sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. Dexmedetomidine injection should be administered by continuous infusion not to exceed 24 hours.
Dexmedetomidine injection has been continuously infused in mechanically ventilated adult patients prior to extubation, during extubation, and post-extubation. It is not necessary to discontinue dexmedetomidine injection prior to extubation.
Dexmedetomidine injection is indicated for sedation of non-intubated adult patients prior to and/or during surgical and other procedures.
Dexmedetomidine injection is indicated for sedation of non-intubated pediatric patients aged 1 month to less than 18 years prior to and during non-invasive procedures.
INDICATION | DOSAGE AND ADMINISTRATION |
Initiation of Intensive Care Unit Sedation | For adult patients: a loading infusion of one mcg/kg over 10 minutes. For adult patients being converted from alternate sedative therapy: a loading dose may not be required. For patients over 65 years of age: Consider a dose reduction [see Use in Specific Populations (8.5)]. For adult patients with impaired hepatic function: Consider a dose reduction [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)]. |
Maintenance of Intensive Care Unit Sedation | For adult patients: a maintenance infusion of 0.2 mcg/kg/hour to 0.7 mcg/kg/hour. The rate of the maintenance infusion should be adjusted to achieve the desired level of sedation. For patients over 65 years of age: Consider a dose reduction [see Use in Specific Populations (8.5)]. For adult patients with impaired hepatic function: Consider a dose reduction [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)]. |
Initiation of Procedural Sedation | For adult patients: a loading infusion of one mcg/kg over 10 minutes. For less invasive procedures such as ophthalmic surgery, a loading infusion of 0.5 mcg/kg given over 10 minutes may be suitable. For awake fiberoptic intubation in adult patients: a loading infusion of one mcg/kg over 10 minutes. For patients over 65 years of age: a loading infusion of 0.5 mcg/kg over 10 minutes [see Use in Specific Populations (8.5)]. For adult patients with impaired hepatic function: Consider a dose reduction [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)]. |
Maintenance of Procedural Sedation | For adult patients: the maintenance infusion is generally initiated at 0.6 mcg/kg/hour and titrated to achieve desired clinical effect with doses ranging from 0.2 mcg/kg/hour to 1 mcg/kg/hour. Adjust the rate of the maintenance infusion to achieve the targeted level of sedation. For awake fiberoptic intubation in adult patients: a maintenance infusion of 0.7 mcg/kg/hour is recommended until the endotracheal tube is secured. For patients over 65 years of age: Consider a dose reduction [see Use in Specific Populations (8.5)]. For adult patients with impaired hepatic function: Consider a dose reduction [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)]. |
INDICATION | DOSAGE AND ADMINISTRATION |
Initiation of Sedation During Non-invasive Procedures | For pediatric patients:
Consider a reduction in dosage if clinically indicated. |
Maintenance of Sedation During Non-invasive Procedures | For pediatric patients:
As clinically warranted, titrate the maintenance dose to individual patient clinical response. |
Due to possible pharmacodynamic interactions, a reduction in dosage of dexmedetomidine injection or other concomitant anesthetics, sedatives, hypnotics or opioids may be required when co-administered [see Drug Interactions (7.1)].
Dosage reductions may need to be considered for adult patients with hepatic impairment, and geriatric patients [see Warnings and Precautions (5.9) , Use in Specific Populations (8.6), Clinical Pharmacology (12.3)].
Strict aseptic technique must always be maintained during handling of dexmedetomidine injection.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if product is discolored or if precipitate matter is present.
Dexmedetomidine injection must be diluted with 0.9% sodium chloride injection to achieve required concentration (4 mcg/mL) prior to administration. Preparation of solutions is the same, whether for the loading dose or maintenance infusion.
To prepare the infusion, withdraw 2 mL of dexmedetomidine injection, and add to 48 mL of 0.9% sodium chloride injection to a total of 50 mL. Shake gently to mix well.
Discard unused portion.
Dexmedetomidine injection infusion should not be co-administered through the same intravenous catheter with blood or plasma because physical compatibility has not been established.
Dexmedetomidine injection has been shown to be incompatible when administered with the following drugs: amphotericin B, diazepam.
Dexmedetomidine injection has been shown to be compatible when administered with the following intravenous fluids:
Compatibility studies have demonstrated the potential for absorption of dexmedetomidine injection to some types of natural rubber. Although dexmedetomidine injection is dosed to effect, it is advisable to use administration components made with synthetic or coated natural rubber gaskets.
Dexmedetomidine Injection USP, 200 mcg/2 mL (100 mcg/mL) is a clear and colorless solution in a single-dose vial, to be used after dilution.
None.
Dexmedetomidine injection should be administered only by persons skilled in the management of patients in the intensive care or operating room setting. Due to the known pharmacological effects of dexmedetomidine injection, patients should be continuously monitored while receiving dexmedetomidine injection.
Clinically significant episodes of bradycardia and sinus arrest have been reported with dexmedetomidine injection administration in young, healthy adult volunteers with high vagal tone or with different routes of administration including rapid intravenous or bolus administration.
Reports of hypotension and bradycardia have been associated with dexmedetomidine injection infusion. Some of these cases have resulted in fatalities. If medical intervention is required, treatment may include decreasing or stopping the infusion of dexmedetomidine injection, increasing the rate of intravenous fluid administration, elevation of the lower extremities, and use of pressor agents. Because dexmedetomidine injection has the potential to augment bradycardia induced by vagal stimuli, clinicians should be prepared to intervene. The intravenous administration of anticholinergic agents (e.g., glycopyrrolate, atropine) should be considered to modify vagal tone. In clinical trials, glycopyrrolate or atropine were effective in the treatment of most episodes of dexmedetomidine injection-induced bradycardia. However, in some patients with significant cardiovascular dysfunction, more advanced resuscitative measures were required.
Caution should be exercised when administering dexmedetomidine injection to patients with advanced heart block and/or severe ventricular dysfunction. Because dexmedetomidine injection decreases sympathetic nervous system activity, hypotension and/or bradycardia may be expected to be more pronounced in patients with hypovolemia, diabetes mellitus, or chronic hypertension and in elderly patients.
In clinical trials where other vasodilators or negative chronotropic agents were co-administered with dexmedetomidine injection an additive pharmacodynamic effect was not observed. Nonetheless, caution should be used when such agents are administered concomitantly with dexmedetomidine injection.
Transient hypertension has been observed primarily during the loading dose in association with the initial peripheral vasoconstrictive effects of dexmedetomidine injection. Treatment of the transient hypertension has generally not been necessary, although reduction of the loading infusion rate may be desirable.
Some patients receiving dexmedetomidine injection have been observed to be arousable and alert when stimulated. This alone should not be considered as evidence of lack of efficacy in the absence of other clinical signs and symptoms.
With administration up to 7 days, regardless of dose, 12 (5%) dexmedetomidine injection adult subjects experienced at least 1 event related to withdrawal within the first 24 hours after discontinuing study drug and 7 (3%) dexmedetomidine injection adult subjects experienced at least 1 event 24 to 48 hours after end of study drug. The most common events were nausea, vomiting, and agitation [see Adverse Reactions (6.1)].
In adult subjects, tachycardia and hypertension requiring intervention in the 48 hours following study drug discontinuation occurred at frequencies of < 5%.
In adult subjects, withdrawal symptoms were not seen after discontinuation of short-term infusions of dexmedetomidine injection (< 6 hours).
In pediatric patients, mild transient withdrawal symptoms of emergence delirium or agitation were seen after discontinuation of short-term infusions of dexmedetomidine injection (< 2 hours) [see Adverse Reactions (6.1)].
Cases of diabetes insipidus (DI) have been reported with use of dexmedetomidine in the setting of sedation. Signs of DI in this setting include polyuria (output > 125 mL/hr), diluted urine (osmolality < 300 mOsm/kg), and hypernatremia (serum sodium > 145 mmol/L). If unrecognized, this condition can lead to hemodynamic instability including unstable blood pressure and increased risk of other cardiovascular sequelae.
In reported cases, signs of DI have spontaneously resolved following discontinuation of dexmedetomidine, with resolution often occurring after 24 hours. Monitor urine output and laboratory data for signs of DI during and after dexmedetomidine administration. If DI is suspected, adjust fluid management, provide supportive care, and consider discontinuing dexmedetomidine. If such care is insufficient, or in a setting where dexmedetomidine is used for an extended treatment period, consider expert consultation to assist with patient management.
Use of dexmedetomidine beyond 24 hours has been associated with tolerance and tachyphylaxis and a dose-related increase in adverse reactions [see Adverse Reactions (6.1)].
Dexmedetomidine injection may induce hyperthermia or pyrexia, which may be resistant to traditional cooling methods, such as administration of cooled intravenous fluids and antipyretic medications. Discontinue dexmedetomidine injection if drug-related hyperthermia or pyrexia is suspected and monitor patients until body temperature normalizes.
Since dexmedetomidine clearance decreases with severity of hepatic impairment, dose reduction should be considered in patients with impaired hepatic function [see Dosage and Administration (2.2, 2.3)].
The following clinically significant adverse reactions are described elsewhere in the labeling:
Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Most common treatment-emergent adverse reactions, occurring in greater than 2% of adult patients in both Intensive Care Unit and procedural sedation studies include hypotension, bradycardia and dry mouth.
Adverse reaction information is derived from the continuous infusion trials of dexmedetomidine injection for sedation in the Intensive Care Unit setting in which 1,007 adult patients received dexmedetomidine injection. The mean total dose was 7.4 mcg/kg (range: 0.8 to 84.1), mean dose per hour was 0.5 mcg/kg/hr (range: 0.1 to 6.0) and the mean duration of infusion of 15.9 hours (range: 0.2 to 157.2). The population was between 17 to 88 years of age, 43% ≥ 65 years of age, 77% male and 93% Caucasian. Treatment-emergent adverse reactions occurring at an incidence of > 2% are provided in Table 3. The most frequent adverse reactions were hypotension, bradycardia and dry mouth [see Warnings and Precautions (5.2)].
Adverse Event | All Dexmedetomidine Injection | Randomized Dexmedetomidine Injection (N = 798) (%) | Placebo (N = 400) (%) | Propofol (N = 188) (%) |
Hypotension | 25% | 24% | 12% | 13% |
Hypertension | 12% | 13% | 19% | 4% |
Nausea | 9% | 9% | 9% | 11% |
Bradycardia | 5% | 5% | 3% | 0 |
Atrial Fibrillation | 4% | 5% | 3% | 7% |
Pyrexia | 4% | 4% | 4% | 4% |
Dry Mouth | 4% | 3% | 1% | 1% |
Vomiting | 3% | 3% | 5% | 3% |
Hypovolemia | 3% | 3% | 2% | 5% |
Atelectasis | 3% | 3% | 3% | 6% |
Pleural Effusion | 2% | 2% | 1% | 6% |
Agitation | 2% | 2% | 3% | 1% |
Tachycardia | 2% | 2% | 4% | 1% |
Anemia | 2% | 2% | 2% | 2% |
Hyperthermia | 2% | 2% | 3% | 0 |
Chills | 2% | 2% | 3% | 2% |
Hyperglycemia | 2% | 2% | 2% | 3% |
Hypoxia | 2% | 2% | 2% | 3% |
Post-procedural Hemorrhage | 2% | 2% | 3% | 4% |
Pulmonary Edema | 1% | 1% | 1% | 3% |
Hypocalcemia | 1% | 1% | 0 | 2% |
Acidosis | 1% | 1% | 1% | 2% |
Urine Output Decreased | 1% | 1% | 0 | 2% |
Sinus Tachycardia | 1% | 1% | 1% | 2% |
Ventricular Tachycardia | < 1% | 1% | 1% | 5% |
Wheezing | < 1% | 1% | 0 | 2% |
Edema Peripheral | < 1% | 0 | 1% | 2% |
* 26 subjects in the all dexmedetomidine injection group and 10 subjects in the randomized dexmedetomidine injection group had exposure for greater than 24 hours.
Adverse reaction information was also derived from the placebo-controlled, continuous infusion trials of dexmedetomidine injection for sedation in the surgical intensive care unit setting in which 387 adult patients received dexmedetomidine injection for less than 24 hours. The most frequently observed treatment-emergent adverse events included hypotension, hypertension, nausea, bradycardia, fever, vomiting, hypoxia, tachycardia and anemia (see Table 4).
Adverse Event | Randomized Dexmedetomidine (N = 387) | Placebo (N = 379) |
Hypotension | 28% | 13% |
Hypertension | 16% | 18% |
Nausea | 11% | 9% |
Bradycardia | 7% | 3% |
Fever | 5% | 4% |
Vomiting | 4% | 6% |
Atrial Fibrillation | 4% | 3% |
Hypoxia | 4% | 4% |
Tachycardia | 3% | 5% |
Hemorrhage | 3% | 4% |
Anemia | 3% | 2% |
Dry Mouth | 3% | 1% |
Rigors | 2% | 3% |
Agitation | 2% | 3% |
Hyperpyrexia | 2% | 3% |
Pain | 2% | 2% |
Hyperglycemia | 2% | 2% |
Acidosis | 2% | 2% |
Pleural Effusion | 2% | 1% |
Oliguria | 2% | < 1% |
Thirst | 2% | < 1% |
In a controlled clinical trial, dexmedetomidine injection was compared to midazolam for ICU sedation exceeding 24 hours duration in adult patients. Key treatment emergent adverse events occurring in dexmedetomidine or midazolam treated adult patients in the randomized active comparator continuous infusion long-term intensive care unit sedation study are provided in Table 5. The number (%) of adult subjects who had a dose-related increase in treatment-emergent adverse events by maintenance adjusted dose rate range in the dexmedetomidine injection group is provided in Table 6.
Adverse Event | Dexmedetomidine (N = 244) | Midazolam (N = 122) |
Hypotension* | 56% | 56% |
Hypotension Requiring Intervention | 28% | 27% |
Bradycardia† | 42% | 19% |
Bradycardia Requiring Intervention | 5% | 1% |
Systolic Hypertension‡ | 28% | 42% |
Tachycardia§ | 25% | 44% |
Tachycardia Requiring Intervention | 10% | 10% |
Diastolic Hypertension | 12% | 15% |
Hypertension | 11% | 15% |
Hypertension Requiring Intervention¶ | 19% | 30% |
Hypokalemia | 9% | 13% |
Pyrexia | 7% | 2% |
Agitation | 7% | 6% |
Hyperglycemia | 7% | 2% |
Constipation | 6% | 6% |
Hypoglycemia | 5% | 6% |
Respiratory Failure | 5% | 3% |
Renal Failure Acute | 2% | 1% |
Acute Respiratory Distress Syndrome | 2% | 1% |
Generalized Edema | 2% | 6% |
Hypomagnesemia | 1% | 7% |
* Hypotension was defined in absolute terms as Systolic blood pressure of < 80 mmHg or Diastolic blood pressure of < 50 mmHg or in relative terms as ≤ 30% lower than pre-study drug infusion value.
† Bradycardia was defined in absolute terms as < 40 bpm or in relative terms as ≤ 30% lower than pre-study drug infusion value.
‡ Hypertension was defined in absolute terms as Systolic blood pressure > 180 mmHg or Diastolic blood pressure of > 100 mmHg or in relative terms as ≥ 30% higher than pre-study drug infusion value.
§ Tachycardia was defined in absolute terms as > 120 bpm or in relative terms as ≥ 30% greater than pre-study drug infusion value.
¶ Includes any type of hypertension.
The following adverse events occurred between 2 and 5% for dexmedetomidine injection and midazolam, respectively: renal failure acute (2.5%, 0.8%), acute respiratory distress syndrome (2.5%, 0.8%), and respiratory failure (4.5%, 3.3%).
Dexmedetomidine Injection (mcg/kg/hr) | |||
Adverse Event | ≤ 0.7* (N = 95) | > 0.7 to ≤ 1.1 (N = 78) | > 1.1 (N = 71) |
Constipation | 6% | 5% | 14% |
Agitation | 5% | 8% | 14% |
Anxiety | 5% | 5% | 9% |
Edema Peripheral | 3% | 5% | 7% |
Atrial Fibrillation | 2% | 4% | 9% |
Respiratory Failure | 2% | 6% | 10% |
Acute Respiratory Distress Syndrome | 1% | 3% | 9% |
* Average maintenance dose over the entire study drug administration.
Adverse reaction information is derived from the two trials for adult procedural sedation [see Clinical Studies (14.2)] in which 318 adult patients received dexmedetomidine injection. The mean total dose was 1.6 mcg/kg (range: 0.5 to 6.7), mean dose per hour was 1.3 mcg/kg/hr (range: 0.3 to 6.1) and the mean duration of infusion of 1.5 hours (range: 0.1 to 6.2). The population was between 18 to 93 years of age, ASA I-IV, 30% ≥ 65 years of age, 52% male and 61% Caucasian.
Treatment-emergent adverse reactions occurring in adults at an incidence of > 2% are provided in Table 7. The most frequent adverse reactions were hypotension, bradycardia, and dry mouth [see Warnings and Precautions (5.2)]. Pre-specified criteria for the vital signs to be reported as adverse reactions are footnoted below the table. The decrease in respiratory rate and hypoxia was similar between dexmedetomidine injection and comparator groups in both studies.
Adverse Event | Dexmedetomidine Injection | Placebo |
Hypotension* | 54% | 30% |
Respiratory Depression† | 37% | 32% |
Bradycardia‡ | 14% | 4% |
Hypertension§ | 13% | 24% |
Tachycardia¶ | 5% | 17% |
Nausea | 3% | 2% |
Dry Mouth | 3% | 1% |
Hypoxia# | 2% | 3% |
Bradypnea | 2% | 4% |
* Hypotension was defined in absolute and relative terms as Systolic blood pressure of < 80 mmHg or ≤ 30% lower than pre-study drug infusion value, or Diastolic blood pressure of < 50 mmHg.
† Respiratory depression was defined in absolute and relative terms as respiratory rate (RR) < 8 beats per minute or > 25% decrease from baseline.
‡ Bradycardia was defined in absolute and relative terms as < 40 beats per minute or ≤ 30% lower than pre-study drug infusion value. Subjects in Study 2 were pretreated with glycopyrrolate 0.1 mg intravenously before receiving study drug [see Clinical Studies (14.2)].
§ Hypertension was defined in absolute and relative terms as Systolic blood pressure > 180 mmHg or ≥ 30% higher than pre-study drug infusion value or Diastolic blood pressure of > 100 mmHg.
¶ Tachycardia was defined in absolute and relative terms as > 120 beats per minute or ≥ 30% greater than pre-study drug infusion value.
# Hypoxia was defined in absolute and relative terms as SpO2 < 90% or 10% decrease from baseline.
Adverse reaction information is derived from a trial for sedation of pediatric procedural during a non-invasive procedure [see Clinical Studies (14.2)] in which 122 pediatric patients aged 1 month to less than 17 years undergoing magnetic resonance imaging (MRI) scans received dexmedetomidine injection. In pediatric patients 1 month to less than 2 years old, the median total dose for the dexmedetomidine injection low, middle, and high dose treatment groups was 8.30, 18.90, and 22.75 mcg, respectively. The median duration of treatment ranged from 52.5 to 69 minutes across treatment groups. In pediatric patients 2 to less than 17 years old, the median total dose for the dexmedetomidine injection low, middle, and high dose treatment groups was 21.30, 43.90, and 80.25 mcg, respectively. The median duration of treatment ranged from 56.5 to 66 minutes across treatment groups.
All-causality treatment-emergent adverse reactions occurring in the combined age group of pediatric patients during the procedure at an incidence of > 5% are provided in Table 8. The most frequent treatment-emergent adverse events were bradypnea, bradycardia, hypertension, and hypotension [see Warnings and Precautions (5.2, 5.3)]. In the combined age group and in each age group, increased incidence in bradycardia and hypertension was observed with increasing dexmedetomidine injection dose. Mild transient withdrawal symptoms of emergence delirium or agitation occurred in 3 of 122 patients after discontinuation of dexmedetomidine injection infusion [see Warnings and Precautions (5.5)]. All reported treatment-emergent adverse reactions were mild to moderate in severity and the majority resolved without medical intervention. No subject in the study required airway intervention, including a jaw thrust or insertion of a nasal or oral airway. A similar profile was observed in the pediatric patients 1 month to less than 2 years old and in pediatric patients 2 to less than 17 years old. Pre-specified criteria for the vital signs to be reported as adverse events are footnoted below the table.
| N = Number of pediatric patients evaluable for adverse events. | ||||
Dexmedetomidine | Dexmedetomidine | Dexmedetomidine | Total | |
Number (%) of Pediatric Patients | n (%) | n (%) | n (%) | n (%) |
Adverse Event | ||||
Bradypnea* | 33 (79) | 27 (64) | 22 (58) | 82 (67) |
Bradycardia† | 24 (57) | 24 (57) | 27 (71) | 75 (62) |
Hypertension‡ | 11 (26) | 17 (41) | 18 (47) | 46 (38) |
Hypotension§ | 13 (31) | 11 (26) | 6 (16) | 30 (25) |
Hypoxia¶ | 6 (14) | 3 (7) | 1 (3) | 10 (8) |
Diastolic Hypertension | 3 (7) | 3 (7) | 4 (11) | 10 (8) |
Systolic Hypertension | 1 (2) | 5 (12) | 3 (8) | 9 (7) |
Tachycardia | 3 (7) | 1 (2) | 1 (3) | 5 (4) |
* Bradypnea was defined as respiratory rate < 1st centile of the age adjusted normal range.
† Bradycardia was defined as a decrease in HR of 30% from baseline or absolute HR ≤ 1st centile of the age adjusted normal range.
‡ For pediatric patients 1 month to less than 1 year old, hypertension was defined as supine systolic blood pressure ≥ 104 mm/Hg and/or diastolic blood pressure ≥ 56 mmHg measurements. For pediatric patients 1 to less than 17 years old: hypertension was defined as supine systolic blood pressure and/or diastolic blood pressure measurements ≥ 95th percentile for gender, age, and height.
§ Hypotension was defined as a decrease in systolic blood pressure ≥ 30% from baseline.
¶ Hypoxia was defined as oxygen saturation < 90% for any duration.
The following adverse reactions have been identified during post-approval use of dexmedetomidine injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Hypotension and bradycardia were the most common adverse reactions associated with the use of dexmedetomidine injection during post-approval use of the drug.
System Organ Class | Preferred Term |
Blood and Lymphatic System Disorders | Anemia |
Cardiac Disorders | Arrhythmia, atrial fibrillation, atrioventricular block, bradycardia, cardiac arrest, cardiac disorder, extrasystoles, myocardial infarction, supraventricular tachycardia, tachycardia, ventricular arrhythmia, ventricular tachycardia |
Eye Disorders | Photopsia, visual impairment |
Gastrointestinal Disorders | Abdominal pain, diarrhea, nausea, vomiting |
General Disorders and Administration Site Conditions | Chills, hyperpyrexia, pain, pyrexia, thirst |
Hepatobiliary Disorders | Hepatic function abnormal, hyperbilirubinemia |
Investigations | Alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood urea increased, electrocardiogram T wave inversion, gammaglutamyltransferase increased, electrocardiogram QT prolonged |
Metabolism and Nutrition Disorders | Acidosis, hyperkalemia, hypoglycemia, hypovolemia, hypernatremia, diabetes insipidus (Cases of diabetes insipidus, with associated polyuria, dilute urine, and hypernatremia, have been reported) |
Nervous System Disorders | Convulsion, dizziness, headache, neuralgia, neuritis, speech disorder |
Psychiatric Disorders | Agitation, confusional state, delirium, hallucination, illusion |
Renal and Urinary Disorders | Oliguria, polyuria |
Respiratory, Thoracic and Mediastinal Disorders | Apnea, bronchospasm, dyspnea, hypercapnia, hypoventilation, hypoxia, pulmonary congestion, respiratory acidosis |
Skin and Subcutaneous Tissue Disorders | Hyperhidrosis, pruritus, rash, urticaria |
Surgical and Medical Procedures | Light anesthesia |
Vascular Disorders | Blood pressure fluctuation, hemorrhage, hypertension, hypotension |
Co-administration of dexmedetomidine injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam. No pharmacokinetic interactions between dexmedetomidine injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine injection, a reduction in dosage of dexmedetomidine injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.
In one study of 10 healthy adult volunteers, administration of dexmedetomidine injection for 45 minutes at a plasma concentration of one ng/mL resulted in no clinically meaningful increases in the magnitude of neuromuscular blockade associated with rocuronium administration.
Available data from published randomized controlled trials and case reports over several decades of use with intravenously administered dexmedetomidine during pregnancy have not identified a drug-associated risk of major birth defects and miscarriage; however, the reported exposures occurred after the first trimester. Most of the available data are based on studies with exposures that occurred at the time of caesarean section delivery, and these studies have not identified an adverse effect on maternal outcomes or infant Apgar scores. Available data indicate that dexmedetomidine crosses the placenta.
In animal reproduction studies, fetal toxicity that lower fetal viability and reduced live fetuses occurred with subcutaneous administration of dexmedetomidine to pregnant rats during organogenesis at doses 1.8 times the maximum recommended human dose (MRHD) of 17.8 mcg/kg/day.
Developmental toxicity (low pup weights and adult offspring weights, decreased F1 grip strength, increased early implantation loss and decreased viability of second-generation offspring) occurred when pregnant rats were subcutaneously administered dexmedetomidine at doses less than the clinical dose from late pregnancy through lactation and weaning (see Data).
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
Increased post-implantation losses and reduced live fetuses in the presence of maternal toxicity (i.e., decreased body weight) were noted in a rat embryo-fetal development study in which pregnant dams were administered subcutaneous doses of dexmedetomidine 200 mcg/kg/day (equivalent to 1.8 times the intravenous MRHD of 17.8 mcg/kg/day based on body surface area [BSA]) during the period of organogenesis (Gestation Day [GD] 6 to 15). No malformations were reported.
No malformations or embryo-fetal toxicity were noted in a rabbit embryo-fetal development study in which pregnant does were administered dexmedetomidine intravenously at doses of up to 96 mcg/kg/day (approximately half the human exposure at the MRHD based on AUC) during the period of organogenesis (GD 6 to 18).
Reduced pup and adult offspring birth weights, and grip strength were reported in a rat developmental toxicology study in which pregnant females were administered dexmedetomidine subcutaneously at doses of 8 mcg/kg/day (0.07 times the MRHD based on BSA) during late pregnancy through lactation and weaning (GD 16 to postnatal day [PND] 25). Decreased viability of second generation offspring and an increase in early implantation loss along with delayed motor development occurred in the 32 mcg/kg/day group (equivalent to less than the clinical dose based on BSA) when first generation offspring were allowed to mate. This study limited dosing to hard palate closure (GD 15 to 18) through weaning instead of dosing from implantation (GD 6 to 7) to weaning (PND 21).
In a study in the pregnant rat, placental transfer of dexmedetomidine was observed when radiolabeled dexmedetomidine was administered subcutaneously.
Available published literature reports the presence of dexmedetomidine in human milk following intravenous administration (see Data). There is no information regarding the effects of dexmedetomidine on the breastfed infant or the effects on milk production. Advise women to monitor the breastfed infant for irritability. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for dexmedetomidine injection and any potential adverse effects on the breastfed infant from dexmedetomidine injection or from the underlying condition.
In two published clinical studies, a total of 14 women were given intravenous dexmedetomidine 6 mcg/kg/hour for 10 minutes after delivery followed by continuous infusion of 0.2 mcg/kg/hour to 0.7 mcg/kg/hour. Breast milk and maternal blood samples were collected at 0, 6, 12, and 24 hours after discontinuation of dexmedetomidine. Plasma and milk dexmedetomidine concentrations were detectable up to 6 hours in most subjects, up to 12 hours in one subject and undetectable in all at 24 hours. The milk-to-plasma ratio from single paired maternal milk and plasma concentrations at each time point ranged from 0.53 to 0.95. The relative infant dose was estimated to range from 0.02 to 0.098%.
The safety and efficacy of dexmedetomidine injection have been established in pediatric patients 1 month to less than 18 years of age for sedation during non-invasive procedures. Use in this age group is based on one randomized double-blind, dose-ranging safety and efficacy trial in non-intubated pediatric patients 1 month to less than 17 years of age who required sedation prior to undergoing MRI scans [see Clinical Studies (14.2)]. An increase in frequency of bradypnea, bradycardia, hypertension and hypotension was observed in pediatric patients treated with dexmedetomidine injection [see Adverse Reactions (6.1)]. The overall safety profile of dexmedetomidine injection in pediatric patients was consistent with the known safety profile in adults [see Adverse Reactions (6.1)].
The safety and effectiveness of dexmedetomidine injection have not been established in pediatric patients less than 1 month of age.
The safety and efficacy of dexmedetomidine injection have not been established in pediatric patients for ICU sedation. One assessor-blinded trial in pediatric patients and two open label studies in neonates were conducted to assess efficacy for ICU sedation. These studies did not meet their primary efficacy endpoints and the safety data submitted were insufficient to fully characterize the safety profile of dexmedetomidine injection for these patient populations.
A total of 729 patients in the clinical studies were 65 years of age and over. A total of 200 patients were 75 years of age and over. In patients greater than 65 years of age, a higher incidence of bradycardia and hypotension was observed following administration of dexmedetomidine injection [see Warnings and Precautions (5.2)]. Therefore, a dose reduction may be considered in patients over 65 years of age [see Dosage and Administration (2.2, 2.3), Clinical Pharmacology (12.3)].
A total of 131 patients in the clinical studies were 65 years of age and over. A total of 47 patients were 75 years of age and over. Hypotension occurred in a higher incidence in dexmedetomidine injection-treated patients 65 years or older (72%) and 75 years or older (74%) as compared to patients < 65 years (47%). A reduced loading dose of 0.5 mcg/kg given over 10 minutes is recommended and a reduction in the maintenance infusion should be considered for patients greater than 65 years of age.
Since dexmedetomidine clearance decreases with increasing severity of hepatic impairment, dose reduction should be considered in patients with impaired hepatic function [see Dosage and Administration (2.2, 2.3), Clinical Pharmacology (12.3)].
Dexmedetomidine injection (dexmedetomidine hydrochloride) is not a controlled substance.
The dependence potential of dexmedetomidine injection has not been studied in humans. However, since studies in rodents and primates have demonstrated that dexmedetomidine injection exhibits pharmacologic actions similar to those of clonidine, it is possible that dexmedetomidine injection may produce a clonidine-like withdrawal syndrome upon abrupt discontinuation [see Warnings and Precautions (5.5)].
The tolerability of dexmedetomidine injection was studied in one study in which healthy adult subjects were administered doses at and above the recommended dose of 0.2 mcg/kg/hr to 0.7 mcg/kg/hr. The maximum blood concentration achieved in this study was approximately 13 times the upper boundary of the therapeutic range. The most notable effects observed in two subjects who achieved the highest doses were first degree atrioventricular block and second-degree heart block. No hemodynamic compromise was noted with the atrioventricular block and the heart block resolved spontaneously within one minute.
Five adult patients received an overdose of dexmedetomidine injection in the intensive care unit sedation studies. Two of these patients had no symptoms reported; one patient received a 2 mcg/kg loading dose over 10 minutes (twice the recommended loading dose) and one patient received a maintenance infusion of 0.8 mcg/kg/hr. Two other patients who received a 2 mcg/kg loading dose over 10 minutes, experienced bradycardia and/or hypotension. One patient who received a loading bolus dose of undiluted dexmedetomidine injection (19.4 mcg/kg), had cardiac arrest from which he was successfully resuscitated.
Dexmedetomidine injection USP, (100 mcg/mL), is a sterile, nonpyrogenic solution suitable for intravenous infusion following dilution.
Dexmedetomidine injection contains dexmedetomidine hydrochloride as the active pharmaceutical ingredient. Dexmedetomidine hydrochloride is a central alpha2-adrenergic agonist. Dexmedetomidine hydrochloride is the S-enantiomer of medetomidine. Dexmedetomidine hydrochloride chemical name is 1H-Imidazole, 4-[1-(2,3-dimethylphenyl)ethyl]-, monohydrochloride, (S)-;. Dexmedetomidine hydrochloride has a molecular weight of 236.74 and the empirical formula is C13H16N2 • HCl and the structural formula is:
Dexmedetomidine hydrochloride, USP is a solid, white or almost white powder that is freely soluble in water and has a pKa of 7.1. Its partition coefficient in-octanol: water at pH 7.4 is 2.89.
Dexmedetomidine injection is intended to be used after dilution. It is supplied as a clear, colorless, isotonic solution with a pH between 4.5 to 7.0. Each mL contains 118 mcg of dexmedetomidine hydrochloride (equivalent to 100 mcg or 0.1 mg of dexmedetomidine) and 9 mg of sodium chloride in water for injection. The solution is preservative-free and contains no additives or chemical stabilizers. Each mL of dexmedetomidine injection contains 9 mg of sodium and less than 5 mg each of phosphorus and potassium.
Dexmedetomidine injection is a relatively selective centrally acting alpha2-adrenergic agonist with sedative properties. Alpha2 selectivity is observed in animals following slow intravenous infusion of low and medium doses (10-300 mcg/kg). Both alpha1 and alpha2 activity is observed following slow intravenous infusion of high doses (≥ 1,000 mcg/kg) or with rapid intravenous administration.
In a study in healthy adult volunteers (N = 10), respiratory rate and oxygen saturation remained within normal limits and there was no evidence of respiratory depression when dexmedetomidine injection was administered by intravenous infusion at doses within the recommended dose range (0.2 mcg/kg/hr to 0.7 mcg/kg/hr).
Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t1/2) of approximately 6 minutes; a terminal elimination half-life (t1/2) of approximately 2 hours; and steady-state volume of distribution (Vss) of approximately 118 liters. Clearance is estimated to be approximately 39 L/h. The mean body weight associated with this clearance estimate was 72 kg.
Dexmedetomidine exhibits linear pharmacokinetics in the dosage range of 0.2 mcg/kg/hr to 0.7 mcg/kg/hr when administered to adults by intravenous infusion for up to 24 hours. Table 10 shows the main pharmacokinetic parameters when dexmedetomidine injection was infused (after appropriate loading doses) at maintenance infusion rates of 0.17 mcg/kg/hr (target plasma concentration of 0.3 ng/mL) for 12 and 24 hours, 0.33 mcg/kg/hr (target plasma concentration of 0.6 ng/mL) for 24 hours, and 0.70 mcg/kg/hr (target plasma concentration of 1.25 ng/mL) for 24 hours.
| Abbreviations: t1/2 = half-life, CL = clearance, Vss = steady-state volume of distribution. | ||||
Loading Infusion (min)/Total Infusion Duration (hrs) | ||||
10 min/12 hrs | 10 min/24 hrs | 10 min/24 hrs | 35 min/24 hrs | |
Dexmedetomidine Target Plasma Concentration (ng/mL) and Dose (mcg/kg/hr) | ||||
Parameter | 0.3/0.17 | 0.3/0.17 | 0.6/0.33 | 1.25/0.70 |
t1/2 *, hour | 1.78 ± 0.30 | 2.22 ± 0.59 | 2.23 ± 0.21 | 2.50 ± 0.61 |
CL, liter/hour | 46.3 ± 8.3 | 43.1 ± 6.5 | 35.3 ± 6.8 | 36.5 ± 7.5 |
Vss, liter | 88.7 ± 22.9 | 102.4 ± 20.3 | 93.6 ± 17.0 | 99.6 ± 17.8 |
Avg Css †, ng/mL | 0.27 ± 0.05 | 0.27 ± 0.05 | 0.67 ± 0.10 | 1.37 ± 0.20 |
* Presented as harmonic mean and pseudo standard deviation.
† Mean Css = Average steady-state concentration of dexmedetomidine. The mean Css was calculated based on post-dose sampling from 2.5 to 9 hours samples for 12 hour infusion and post-dose sampling from 2.5 to 18 hours for 24 hour infusions.
The loading doses for each of the above indicated groups were 0.5, 0.5, 1 and 2.2 mcg/kg, respectively.
Dexmedetomidine pharmacokinetic parameters in adults after dexmedetomidine injection maintenance doses of 0.2 mcg/kg/hr to 1.4 mcg/kg/hr for > 24 hours were similar to the pharmacokinetic (PK) parameters after dexmedetomidine injection maintenance dosing for < 24 hours in other studies. The values for clearance (CL), volume of distribution (V), and t1/2 were 39.4 L/hr, 152 L, and 2.67 hours, respectively.
The steady-state volume of distribution (Vss) of dexmedetomidine was approximately 118 liters. Dexmedetomidine protein binding was assessed in the plasma of normal healthy male and female subjects. The average protein binding was 94% and was constant across the different plasma concentrations tested. Protein binding was similar in males and females. The fraction of dexmedetomidine that was bound to plasma proteins was significantly decreased in subjects with hepatic impairment compared to healthy subjects.
The potential for protein binding displacement of dexmedetomidine by fentanyl, ketorolac, theophylline, digoxin and lidocaine was explored in vitro, and negligible changes in the plasma protein binding of dexmedetomidine were observed. The potential for protein binding displacement of phenytoin, warfarin, ibuprofen, propranolol, theophylline and digoxin by dexmedetomidine was explored in vitro and none of these compounds appeared to be significantly displaced by dexmedetomidine.
Dexmedetomidine undergoes almost complete biotransformation with very little unchanged dexmedetomidine excreted in urine and feces. Biotransformation involves both direct glucuronidation as well as cytochrome P450 mediated metabolism. The major metabolic pathways of dexmedetomidine are: direct N-glucuronidation to inactive metabolites; aliphatic hydroxylation (mediated primarily by CYP2A6 with a minor role of CYP1A2, CYP2E1, CYP2D6 and CYP2C19) of dexmedetomidine to generate 3-hydroxy-dexmedetomidine, the glucuronide of 3-hydroxy-dexmedetomidine, and 3-carboxy-dexmedetomidine; and N-methylation of dexmedetomidine to generate 3-hydroxy N-methyl-dexmedetomidine, 3-carboxy N-methyl-dexmedetomidine, and dexmedetomidine-N-methyl O-glucuronide.
The terminal elimination half-life (t1/2) of dexmedetomidine is approximately 2 hours and clearance is estimated to be approximately 39 L/h. A mass balance study demonstrated that after nine days an average of 95% of the radioactivity, following intravenous administration of radiolabeled dexmedetomidine, was recovered in the urine and 4% in the feces. No unchanged dexmedetomidine was detected in the urine. Approximately 85% of the radioactivity recovered in the urine was excreted within 24 hours after the infusion. Fractionation of the radioactivity excreted in urine demonstrated that products of N-glucuronidation accounted for approximately 34% of the cumulative urinary excretion. In addition, aliphatic hydroxylation of parent drug to form 3-hydroxy-dexmedetomidine, the glucuronide of 3-hydroxy-dexmedetomidine, and 3-carboxylic acid-dexmedetomidine together represented approximately 14% of the dose in urine. N-methylation of dexmedetomidine to form 3-hydroxy N-methyl dexmedetomidine, 3-carboxy N-methyl dexmedetomidine, and N-methyl O-glucuronide dexmedetomidine accounted for approximately 18% of the dose in urine. The N-Methyl metabolite itself was a minor circulating component and was undetected in urine. Approximately 28% of the urinary metabolites have not been identified.
There was no observed difference in dexmedetomidine injection pharmacokinetics due to sex.
The pharmacokinetic profile of dexmedetomidine injection was not altered by age. There were no differences in the pharmacokinetics of dexmedetomidine injection in young (18–40 years), middle age (41–65 years), and elderly (> 65 years) subjects.
A population PK analysis was conducted with data collected from mechanically ventilated pediatric patients less than 17 years of age from 4 clinical studies. A linear 2-compartment model was found to best characterize the pooled dexmedetomidine concentration data. Mean PK parameters for each age group are summarized in Table 11.
| Abbreviations: CL = plasma clearance, Vc = volume of the central compartment. | |||
Age Group | N | CL (L/h) | Vc (L) |
1 to less than 6 months | 14 | 6.94 (5.46, 8.81) | 4.34 (3.25, 5.81) |
6 to less than 12 months | 15 | 8.15 (7.01, 9.47) | 7.29 (5.57, 9.53) |
12 to less than 24 months | 13 | 10.76 (9.09, 12.74) | 7.35 (5.59, 9.67) |
2 to less than 6 years | 26 | 15.89 (14.00, 18.04) | 13.78 (10.66, 17.83) |
6 to less than 17 years | 28 | 24.45 (19.34, 30.92) | 24.47 (17.06, 35.10) |
In adult subjects with varying degrees of hepatic impairment (Child-Pugh Class A, B, or C), clearance values for dexmedetomidine were lower than in healthy subjects. The mean clearance values for patients with mild, moderate, and severe hepatic impairment were 74%, 64% and 53% of those observed in the normal healthy adult subjects, respectively. Mean clearances for free drug were 59%, 51% and 32% of those observed in the normal healthy adult subjects, respectively.
Although dexmedetomidine injection is dosed to effect, it may be necessary to consider dose reduction in subjects with hepatic impairment [see Dosage and Administration (2.2), Warnings and Precautions (5.9) ].
Dexmedetomidine pharmacokinetics (Cmax, Tmax, AUC, t1/2, CL, and Vss) were not significantly different in patients with severe renal impairment (creatinine clearance: < 30 mL/min) compared to healthy subjects.
In vitro studies in human liver microsomes demonstrated no evidence of cytochrome P450 mediated drug interactions that are likely to be of clinical relevance.
Animal carcinogenicity studies have not been performed with dexmedetomidine.
Dexmedetomidine was not mutagenic in vitro, in either the bacterial reverse mutation assay (E. coli and Salmonella typhimurium) or the mammalian cell forward mutation assay (mouse lymphoma). Dexmedetomidine was clastogenic in the in vitro human lymphocyte chromosome aberration test with, but not without, rat S9 metabolic activation. In contrast, dexmedetomidine was not clastogenic in the in vitro human lymphocyte chromosome aberration test with or without human S9 metabolic activation. Although dexmedetomidine was clastogenic in an in vivo mouse micronucleus test in NMRI mice, there was no evidence of clastogenicity in CD-1 mice.
Fertility in male or female rats was not affected after daily subcutaneous injections of dexmedetomidine at doses up to 54 mcg/kg (less than the maximum recommended human intravenous dose on a mcg/m2 basis) administered from 10 weeks prior to mating in males, and 3 weeks prior to mating and during mating in females.
There were no differences in the adrenocorticotropic hormone (ACTH)-stimulated cortisol response in dogs following a single-dose of dexmedetomidine compared to saline control. However, after continuous subcutaneous infusions of dexmedetomidine at 3 mcg/kg/hr and 10 mcg/kg/hr for one week in dogs (exposures estimated to be within the clinical range), the ACTH-stimulated cortisol response was diminished by approximately 27% and 40%, respectively, compared to saline-treated control animals indicating a dose-dependent adrenal suppression.
The safety and efficacy of dexmedetomidine injection has been evaluated in four randomized, double-blind, placebo-controlled multicenter clinical trials in 1,185 adult patients.
Two randomized, double-blind, parallel-group, placebo-controlled multicenter clinical trials included 754 adult patients being treated in a surgical intensive care unit. All patients were initially intubated and received mechanical ventilation. These trials evaluated the sedative properties of dexmedetomidine injection by comparing the amount of rescue medication (midazolam in one trial and propofol in the second) required to achieve a specified level of sedation (using the standardized Ramsay Sedation Scale) between dexmedetomidine injection and placebo from onset of treatment to extubation or to a total treatment duration of 24 hours. The Ramsay Level of Sedation Scale is displayed in Table 12.
Clinical Score | Level of Sedation Achieved |
6 | Asleep, no response |
5 | Asleep, sluggish response to light glabellar tap or loud auditory stimulus |
4 | Asleep, but with brisk response to light glabellar tap or loud auditory stimulus |
3 | Patient responds to commands |
2 | Patient cooperative, oriented, and tranquil |
1 | Patient anxious, agitated, or restless |
In the first study, 175 adult patients were randomized to receive placebo and 178 to receive dexmedetomidine injection by intravenous infusion at a dose of 0.4 mcg/kg/hr (with allowed adjustment between 0.2 mcg/kg/hr and 0.7 mcg/kg/hr) following an initial loading infusion of one mcg/kg intravenous over 10 minutes. The study drug infusion rate was adjusted to maintain a Ramsay sedation score of ≥ 3. Patients were allowed to receive “rescue” midazolam as needed to augment the study drug infusion. In addition, morphine sulfate was administered for pain as needed. The primary outcome measure for this study was the total amount of rescue medication (midazolam) needed to maintain sedation as specified while intubated. Patients randomized to placebo received significantly more midazolam than patients randomized to dexmedetomidine injection (see Table 13).
A second prospective primary analysis assessed the sedative effects of dexmedetomidine injection by comparing the percentage of adult patients who achieved a Ramsay sedation score of ≥ 3 during intubation without the use of additional rescue medication. A significantly greater percentage of adult patients in the dexmedetomidine injection group maintained a Ramsay sedation score of ≥ 3 without receiving any midazolam rescue compared to the placebo group (see Table 13).
| ITT (intent-to-treat) population includes all randomized patients. | |||
Placebo (N = 175) | Dexmedetomidine Injection (N = 178) | p-value | |
Mean Total Dose (mg) of Midazolam | 19 mg | 5 mg | 0.0011* |
Standard deviation | 53 mg | 19 mg | |
Categorized Midazolam Use | |||
0 mg | 43 (25%) | 108 (61%) | < 0.001† |
0–4 mg | 34 (19%) | 36 (20%) | |
> 4 mg | 98 (56%) | 34 (19%) | |
A prospective secondary analysis assessed the dose of morphine sulfate administered to adult patients in the dexmedetomidine injection and placebo groups. On average, dexmedetomidine injection-treated patients received less morphine sulfate for pain than placebo-treated patients (0.47 versus 0.83 mg/h). In addition, 44% (79 of 178 patients) of dexmedetomidine injection patients received no morphine sulfate for pain versus 19% (33 of 175 patients) in the placebo group.
In a second study, 198 adult patients were randomized to receive placebo and 203 to receive dexmedetomidine injection by intravenous infusion at a dose of 0.4 mcg/kg/hr (with allowed adjustment between 0.2 mcg/kg/hr and 0.7 mcg/kg/hr) following an initial loading infusion of one mcg/kg intravenous over 10 minutes. The study drug infusion was adjusted to maintain a Ramsay sedation score of ≥ 3. Patients were allowed to receive “rescue” propofol as needed to augment the study drug infusion. In addition, morphine sulfate was administered as needed for pain. The primary outcome measure for this study was the total amount of rescue medication (propofol) needed to maintain sedation as specified while intubated.
Adult patients randomized to placebo received significantly more propofol than adult patients randomized to dexmedetomidine injection (see Table 14).
A significantly greater percentage of adult patients in the dexmedetomidine injection group compared to the placebo group maintained a Ramsay sedation score of ≥ 3 without receiving any propofol rescue (see Table 14).
Placebo (N = 198) | Dexmedetomidine Injection (N = 203) | p-value | |
Mean Total Dose (mg) of Propofol | 513 mg | 72 mg | < 0.0001* |
Standard deviation | 782 mg | 249 mg | |
Categorized Propofol Use | |||
0 mg | 47 (24%) | 122 (60%) | < 0.001† |
0–50 mg | 30 (15%) | 43 (21%) | |
> 50 mg | 121 (61%) | 38 (19%) | |
A prospective secondary analysis assessed the dose of morphine sulfate administered to adult patients in the dexmedetomidine injection and placebo groups. On average, dexmedetomidine injection-treated patients received less morphine sulfate for pain than placebo-treated patients (0.43 versus 0.89 mg/h). In addition, 41% (83 of 203 patients) of dexmedetomidine injection patients received no morphine sulfate for pain versus 15% (30 of 198 patients) in the placebo group.
In a controlled clinical trial, dexmedetomidine injection was compared to midazolam for ICU sedation exceeding 24 hours duration. Dexmedetomidine injection was not shown to be superior to midazolam for the primary efficacy endpoint, the percent of time patients were adequately sedated (81% versus 81%). In addition, administration of dexmedetomidine injection for longer than 24 hours was associated with tolerance, tachyphylaxis, and a dose-related increase in adverse events [see Adverse Reactions (6.1)].
The safety and efficacy of dexmedetomidine injection for sedation of non-intubated adult patients prior to and/or during surgical and other procedures was evaluated in two randomized, double-blind, placebo-controlled multicenter clinical trials. Study 1 evaluated the sedative properties of dexmedetomidine injection in adult patients having a variety of elective surgeries/procedures performed under monitored anesthesia care. Study 2 evaluated dexmedetomidine injection in adult patients undergoing awake fiberoptic intubation prior to a surgical or diagnostic procedure.
In Study 1, the sedative properties of dexmedetomidine injection were evaluated by comparing the percent of adult patients not requiring rescue midazolam to achieve a specified level of sedation using the standardized Observer’s Assessment of Alertness/Sedation Scale (see Table 15).
Assessment Categories | ||||
Responsiveness | Speech | Facial Expression | Eyes | Composite Score |
Responds readily to name spoken in normal tone | Normal | Normal | Clear, no ptosis | 5 (alert) |
Lethargic response to name spoken in normal tone | Mild slowing or thickening | Mild relaxation | Glazed or mild ptosis (less than half the eye) | 4 |
Responds only after name is called loudly and/or repeatedly | Slurring or prominent slowing | Marked relaxation (slack jaw) | Glazed and marked ptosis (half the eye or more) | 3 |
Responds only after mild prodding or shaking | Few recognizable words | – | – | 2 |
Does not respond to mild prodding or shaking | – | – | – | 1 (deep sleep) |
Adult patients were randomized to receive a loading infusion of either dexmedetomidine injection 1 mcg/kg, dexmedetomidine injection 0.5 mcg/kg, or placebo (normal saline) given over 10 minutes and followed by a maintenance infusion started at 0.6 mcg/kg/hr. The maintenance infusion of study drug could be titrated from 0.2 mcg/kg/hr to 1 mcg/kg/hr to achieve the targeted sedation score (Observer’s Assessment of Alertness/Sedation Scale ≤ 4). Adult patients were allowed to receive rescue midazolam as needed to achieve and/or maintain an Observer’s Assessment of Alertness/Sedation Scale ≤ 4. After achieving the desired level of sedation, a local or regional anesthetic block was performed. Demographic characteristics were similar between the dexmedetomidine injection and comparator groups. Efficacy results showed that dexmedetomidine injection was more effective than the comparator group when used to sedate non-intubated patients requiring monitored anesthesia care during surgical and other procedures (see Table 15).
In Study 2, the sedative properties of dexmedetomidine injection were evaluated by comparing the percent of adult patients requiring rescue midazolam to achieve or maintain a specified level of sedation using the Ramsay Sedation Scale score ≥ 2 (see Table 12). Adult patients were randomized to receive a loading infusion of dexmedetomidine injection 1 mcg/kg or placebo (normal saline) given over 10 minutes and followed by a fixed maintenance infusion of 0.7 mcg/kg/hr. After achieving the desired level of sedation, topicalization of the airway occurred. Adult patients were allowed to receive rescue midazolam as needed to achieve and/or maintain a Ramsay Sedation Scale ≥ 2. Demographic characteristics were similar between the dexmedetomidine injection and comparator groups. For efficacy results see Table 16.
Study | Loading Infusion | Number of | % Not | Confidence† | Mean (SD) | Confidence |
Study 1 | Dexmedetomidine | 134 | 40 | 37 (27, 48) | 1.4 (1.7) | -2.7 (-3.4, -2.0) |
Dexmedetomidine | 129 | 54 | 51 (40, 62) | 0.9 (1.5) | -3.1 (-3.8, -2.5) | |
Placebo | 63 | 3 | – | 4.1 (3.0) | – | |
Study 2 | Dexmedetomidine | 55 | 53 | 39 (20, 57) | 1.1 (1.5) | -1.8 (-2.7, -0.9) |
Placebo | 50 | 14 | – | 2.9 (3.0) | – |
* Based on ITT population defined as all randomized and treated patients.
† Normal approximation to the binomial with continuity correction.
Pediatric Patients
The safety and efficacy of dexmedetomidine injection for sedation of non-intubated pediatric patients aged 1 month to less than 17 years undergoing MRI scans was evaluated in one randomized, double-blind, dose-ranging, dose-controlled multicenter clinical trial utilizing 3 different dexmedetomidine injection dosages. The sedative properties of dexmedetomidine injection were evaluated by age group and by the percent of pediatric patients at the high dose level versus the low dose level who did not require concomitant propofol to complete the MRI scan.
A total of 122 pediatric patients were randomized to the dexmedetomidine injection low dose group (42 of 122), the middle dose group (42 of 122) or the high dose treatment group (38 of 122). All patients received a dexmedetomidine injection loading dose infusion over 10 minutes followed by a maintenance infusion for the duration of the MRI scan (Table 17). If an adequate level of sedation was not achieved within 5 minutes after the start of the dexmedetomidine injection maintenance infusion, patients could receive concomitant propofol as needed based on clinical judgment to achieve and/or maintain adequate sedation.
Age | High Dose | Middle Dose | Low Dose | |||
Loading | Maintenance | Loading | Maintenance | Loading | Maintenance | |
1 month to less than 2 years | 1.5 mcg/kg | 1.5 mcg/kg/h | 1 mcg/kg | 1 mcg/kg/h | 0.5 mcg/kg | 0.5 mcg/kg/h |
2 to less than 17 years | 2 mcg/kg | 1.5 mcg/kg/h | 1.2 mcg/kg | 1 mcg/kg/h | 0.5 mcg/kg | 0.5 mcg/kg/h |
The primary efficacy results from this pediatric procedural sedation study are summarized in Table 18. In the combined age group, the percent of pediatric patients not requiring concomitant propofol was 14.3% (6/42) in the low dose group and 63.2% (24/38) in the high dose group. The percentage of patients at the dexmedetomidine injection high dose who completed the MRI without concomitant propofol was statistically greater than the percentage in the dexmedetomidine injection low dose group (p < 0.001).
Age Group | High Dose | Middle | Low Dose | High Dose vs. Low Dose | ||
n (%) | n (%) | n (%) | Odds Ratio | p-value | ||
1 month to less than 2 years | N = 59 | 9/18 | 2/21 | 2/20 | 0.18 (0.04, 0.82) | 0.022 |
2 to less than 17 years | N = 63 | 15/20 | 13/21 | 3/22 | 0.05 (0.01, 0.26) | < 0.001 |
Overall | N = 122 | 24/38 | 15/42 | 6/42 | 0.10 (0.03, 0.29) | < 0.001 |
* * Exact 95% CI of proportion of subjects not requiring propofol in each dose level.
† ** p-values; CI is confidence interval of odds ratio.
Secondarily, the sedative properties were also evaluated by examining the percent of time at a target sedation score using the Pediatric Sedation State Scale (PSSS). The PSSS is a validated 6-point scale specifically designed for evaluating pediatric patients undergoing sedation for diagnostic and therapeutic procedures. The PSSS measures the effectiveness and quality of procedural sedation in children. The target sedation level was indicated by a PSSS score of 2 (i.e., patient is quiet [asleep or awake], not moving during procedure, has no frown [or brow furrow] indicating pain or anxiety and no verbalization of any complaint).
In the dexmedetomidine injection high dose group, pediatric patients in both the combined and individual age group were at the target sedation rating scale score (PSSS of 2) for a mean > 87% of the time during the dexmedetomidine injection maintenance infusion. In both the combined and individual age group, an increase in the percentage of time at the target sedation rating scale score (PSSS of 2) was observed with increasing dexmedetomidine injection dosage.
Dexmedetomidine Injection USP, 200 mcg/2 mL (100 mcg/mL) is clear and colorless and is available in:
NDC 67457-251-02
2 mL in a 3 mL single-dose vial, cartons of 25
Do not use if product is discolored or if precipitate matter is present.
The strength is based on the dexmedetomidine base. Discard unused portion.
Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]
Dexmedetomidine injection is indicated for short-term intravenous sedation. Dosage must be individualized and titrated to the desired clinical effect. Blood pressure, heart rate and oxygen levels will be monitored both continuously during the infusion of dexmedetomidine injection and as clinically appropriate after discontinuation.
Sterile, Non-pyrogenic
Preservative Free
Manufactured for:
Mylan Institutional LLC
Morgantown, WV 26505 U.S.A.
Manufactured by:
Mylan Institutional
Galway, Ireland
Revised: 5/2026
MI:DEXDIJ:RX1
NDC 67457-251-02
Dexmedetomidine
Injection, USP
200 mcg/2 mL
(100 mcg/mL) Dexmedetomidine
For Intravenous Infusion Only
MUST BE DILUTED
Rx only 25 x 2 mL Single-Dose Vials
Sterile, Nonpyrogenic
Preservative free
Each mL contains: 118 mcg of dexmedetomidine hydrochloride equivalent to 100 mcg of dexmedetomidine; sodium chloride, 9 mg; water for injection, q.s. The solution is preservative free and contains no additives or chemical stabilizers. pH is 4.5 to 7.0.
Usual Dosage: See accompanying prescribing information.
Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]
Must be diluted with 0.9% Sodium Chloride Injection USP for intravenous use.
Discard unused portion.
MI:251:25C:R8
Manufactured for:
Mylan Institutional LLC
Morgantown, WV 26505 U.S.A.
Manufactured by:
Mylan Institutional
Galway, Ireland
Mylan.com
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 309710 | dexmedeTOMIDine HCl 200 MCG in 2 ML Injection | PSN | 21 |
| 309710 | 2 ML dexmedetomidine 0.1 MG/ML Injection | SCD | 21 |
| 309710 | dexmedetomidine (as dexmedetomidine HCl) 0.1 MG/ML per 2 ML Injection | SY | 21 |
| 309710 | dexmedetomidine (as dexmedetomidine HCl) 100 MCG/ML Injection | SY | 21 |
| Class | Version | Type | Effective |
|---|---|---|---|
| DEXMEDETOMIDINE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 4ec136f1-cd53-4b90-826e-3eaeec54dca0 | Product name | 2 | 20250401 |
| acae4bed-c293-9f7e-61b9-d68b8475ed3a | Product name | 2 | 20230104 |
| 536fa340-f745-6c4e-1ad7-a3c414722bcc | Product name | 9 | 20170706 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 67457-251-00 | Dexmedetomidine | 2 mL in 1 VIAL, GLASS | INJECTION, SOLUTION, CONCENTRATE | 2 | 21 | |
| 67457-251-02 | Dexmedetomidine | 25 in 1 CARTON | INJECTION, SOLUTION, CONCENTRATE | 25 | 21 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 67457-251-00 | ML - Milliliter | 67457-251 | 29ed2165-551f-4979-bd68-ef6f9aa04dd0 | 1 | 2014-09-03 |
| 67457-251-02 | ML - Milliliter | 67457-251 | 16ddaf7e-3658-4af8-9999-ba48c57f965f | 1 | 2014-09-03 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| DEXMEDETOMIDINE HYDROCHLORIDE | ACTIVE INGREDIENT | 1018WH7F9I | 7 | |
| DEXMEDETOMIDINE | ACTIVE MOIETY | 67VB76HONO | 7 | |
| SODIUM CHLORIDE | INACTIVE INGREDIENT | 451W47IQ8X | 7 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 7 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 67457-251 | 67457-251-00, 67457-251-02 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| DEXMEDETOMIDINE HYDROCHLORIDE | 1018WH7F9I | ACTIM |
| SODIUM CHLORIDE | 451W47IQ8X | IACT |
| WATER | 059QF0KO0R | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION, CONCENTRATE / INTRAVENOUS | 0.86 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION, CONCENTRATE / INTRAVENOUS | 0.86 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION, CONCENTRATE / INTRAVENOUS | 0.86 %w/v |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 |
| Application-product | TE code |
|---|---|
| A202881-001 | AP |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | 3a93d1ddd44b… | |
| 2022-10-28 04:53 UTC | 2022-10 | A202881-001 | DEXMEDETOMIDINE HYDROCHLORIDE | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE / INJECTION | AP | 2014-08-18 | f41ea6bd6efb… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A202881-001 | AP | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A202881-001 | AP | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A202881-001 | AP | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A202881-001 | AP | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A202881-001 | AP | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A202881-001 | AP | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A202881-001 | AP | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A202881-001 | AP | 1 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A202881-001 | AP | 1 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A202881-001 | AP | 1 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A202881-001 | AP | 1 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | A202881-001 | AP | 1 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A202881-001 | AP | 1 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A202881-001 | AP | 1 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A202881-001 | AP | 1 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | A202881-001 | AP | 1 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A202881-001 | AP | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | A202881-001 | AP | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | A202881-001 | AP | 1 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | A202881-001 | AP | 1 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | A202881-001 | AP | 1 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | A202881-001 | AP | 1 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A202881-001 | AP | 1 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | A202881-001 | AP | 1 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | A202881-001 | AP | 1 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | A202881-001 | AP | 1 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | A202881-001 | AP | 1 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | A202881-001 | AP | 1 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | A202881-001 | AP | 1 | ea99ee380514… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A202881-001 | AP | 1 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | A202881-001 | AP | 1 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | A202881-001 | AP | 1 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A202881-001 | AP | 1 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A202881-001 | AP | 1 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A202881-001 | AP | 1 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A202881-001 | AP | 1 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | A202881-001 | AP | 1 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | A202881-001 | AP | 1 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A202881-001 | AP | 1 | 3a93d1ddd44b… |
| 2022-10-28 04:53 UTC | 2022-10 | A202881-001 | AP | 1 | f41ea6bd6efb… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Dexmedetomidine | DEXMEDETOMIDINE | Mylan Institutional LLC | ebdfe2e8-30ca-4f18-935a-41bcbbce4937 | 2026-05-18 | Warnings, Adverse reactions | 67457-251-00 67457-251-02 67457-251 67457025102 67457025100 afa561b9-9d6c-47b3-87e6-8d049597a0ed ebdfe2e8-30ca-4f18-935a-41bcbbce4937 |
Adverse event summaries are temporarily unavailable. Other product information remains available.